In the presented work, eosinophils (a cell type that is often difficult to identify reliably using traditional histological stains), were clearly and distinctly visualised using Lumito’s SCIZYS platform and upconverting nanoparticles (UCNPs). The technology provided high contrast and precise localisation, making the cells easily identifiable even in complex tissue environments.

The ability to detect and quantify rare cell populations is an important challenge in both research and drug development, where small but biologically relevant changes can otherwise be overlooked. These results further confirm that Lumito’s technology can extract more reliable and detailed information from tissue samples than conventional methods.

“Highlighting rare cells in tissue samples has long been a challenge. In some of our asthma studies, identifying key cells such as eosinophils proved difficult despite multiple approaches. When we applied Lumito’s SCIZYS platform, the results were striking, these cells became easy to see and simple to quantify. We are confident our customers will be just as impressed as we are,” says Karin von Wachenfeldt, CEO Truly Labs.

The findings build on the collaboration between Lumito and Truly Labs, established in December 2024, that includes pilot studies and method development with an aim to include the SCIZYS technology in Truly Labs’ customer offering. The demonstration at Pharma Outsourcing highlights a new, concrete application area where Lumito’s technology can create immediate value.

Lumito’s SCIZYS platform eliminates background interference and enables high sensitivity detection of biomarkers in tissue and a wide dynamic range, making it particularly well suited for detecting rare cells and subtle biological signals. With this capability now validated and demonstrated, Lumito strengthens its position as a provider of advanced tissue analysis solutions.